石藥集團(01093.HK):“普瑞巴林膠囊”獲藥品註冊批件
格隆匯6月8日丨石藥集團(01093.HK)發佈公吿,公司附屬公司石藥集團歐意藥業有限公司開發的“普瑞巴林膠囊(75mg、150mg)”已獲中國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。
該產品用於治療帶狀皰疹後神經痛及纖維肌痛。普瑞巴林是抑制性神經遞質γ-氨基丁酸(GABA)的結構衍生物,但不影響GABA的吸收和降解。普瑞巴林與中樞神經系統組織中的α2-δ位點具有高親和力,從而減少穀氨酸和去甲腎上腺素等神經遞質的釋放。該產品的獲批將進一步豐富集團在神經系統疾病領域的產品線,為患者提供更多用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.